Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 4/2012

01.08.2012 | Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Anticoagulation-Related Intracranial Hemorrhages

verfasst von: Manoj K. Mittal, Alejandro A. Rabinstein

Erschienen in: Current Atherosclerosis Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Unfractionated heparin, low molecular weight heparin, and warfarin are often used for patients at high risk of thromboembolism and are associated with increased risk of major and even life threatening hemorrhages. They are in use for a long time and have treatment strategies in place in an event of life threatening intracranial hemorrhage. The advent of newer anticoagulants, direct thrombin inhibitors (dabigatran) and two factor Xa inhibitors (rivaroxaban and apixaban), has increased the options of anticoagulation for patients with atrial fibrillation and venous thrombosis, but at the same time, in the absence of an antidote, they have created a great challenge for treating physicians to manage intracranial bleeding related to these agents. In this paper, we will briefly summarize the state of knowledge regarding the risk of anticoagulation-related ICH, and review basic concepts on anticoagulation reversal and the general management of patients with this complication.
Literatur
1.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults. JAMA: The Journal of the American Medical Association. 2001;285:2370–5.CrossRef
2.
Marini C, De Santis F, Sacco S, et al. Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke. Stroke. 2005;36:1115–9.PubMedCrossRef
3.
Atrial Fibrillation Investigators: Atrial Fibrillation A, Anticoagulation Study,, Boston Area Anticoagulation Trial for Atrial Fibrillation Study, Canadian Atrial Fibrillation Anticoagulation Study, Stroke Prevention in Atrial Fibrillation Study, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation: Analysis of Pooled Data From Five Randomized Controlled Trials. Arch Intern Med 1994;154:1449–1457.
4.
Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902.PubMed
5.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146:857–67.PubMed
6.
Jerrgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence. Neurology. 1997;48:891–5.CrossRef
7.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of Clinical Classification Schemes for Predicting Stroke. JAMA: The Journal of the American Medical Association. 2001;285:2864–70.CrossRef
8.
Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. Chest. 2010;137:263–72.PubMedCrossRef
9.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest. 2010;138:1093–100.PubMedCrossRef
10.
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation. Ann Intern Med. 1999;131:492–501.PubMed
11.
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. New England Journal of Medicine 2009;360:2066–2078.
12.
Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657–60.PubMed
13.
Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21:722–7.PubMedCrossRef
14.
Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–21.PubMedCrossRef
15.
Jorpes EEP, Thaning T. Neutralisation of action of heparin by protamine. Lancet 1939:975–976.
16.
Broderick J, Connolly S, Feldmann E, et al. REPRINT Circulation. 2007;116:e391–413.CrossRef
17.
Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral Anticoagulants*. Chest. 2008;133:141S–59.PubMedCrossRef
18.
van Veen JJ, Maclean RM, Hampton KK, et al. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis. 2011;22:565–70.PubMedCrossRef
19.
Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. Journal of Postgraduate Medicine. 2007;53:17–22.PubMedCrossRef
20.
•• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992. A randomized controlled trial showing that apixaban is superior to warfarin in preventing stroke or systemic embolism, with less bleeding, and mortality. PubMedCrossRef
21.
•• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891. A randomized controlled trial showing that rivaroxaban is superior to warfarin in preventing stroke or systemic embolism. PubMedCrossRef
22.
Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med. 2011;13:509–18.PubMedCrossRef
23.
Hart RG, Tonarelli SB, Pearce LA. Avoiding Central Nervous System Bleeding During Antithrombotic Therapy. Stroke. 2005;36:1588–93.PubMedCrossRef
24.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and Management of the Vitamin K Antagonists*. Chest. 2008;133:160S–98.PubMedCrossRef
25.
Wysowski DK, Nourjah P, Swartz L. Bleeding Complications With Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action. Arch Intern Med. 2007;167:1414–9.PubMedCrossRef
26.
Flaherty M, Haverbusch M, Sekar P, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocritical Care. 2006;5:197–201.PubMedCrossRef
27.
Hart RG, Boop BS, Anderson DC. Oral Anticoagulants and Intracranial Hemorrhage: Facts and Hypotheses. Stroke. 1995;26:1471–7.PubMedCrossRef
28.
Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The Effect of Warfarin and Intensity of Anticoagulation on Outcome of Intracerebral Hemorrhage. Arch Intern Med. 2004;164:880–4.PubMedCrossRef
29.
Hylek EM, Go AS, Chang Y, et al. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. N Engl J Med. 2003;349:1019–26.PubMedCrossRef
30.
Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–64.PubMedCrossRef
31.
Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology. 2011;76:1238–44.PubMedCrossRef
32.
Zubkov AY, Mandrekar JN, Claassen DO, Manno EM, Wijdicks EFM, Rabinstein AA. Predictors of Outcome in Warfarin-Related Intracerebral Hemorrhage. Arch Neurol. 2008;65:1320–5.PubMedCrossRef
33.
Biffi A, Battey TWK, Ayres AM, et al. Warfarin-related intraventricular hemorrhage. Neurology. 2011;77:1840–6.PubMedCrossRef
34.
Levine J, Snider R, Finkelstein D, et al. Early edema in warfarin-related intracerebral hemorrhage. Neurocritical Care. 2007;7:58–63.PubMedCrossRef
35.
Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77:477–80.PubMed
36.
•• Morgenstern LB, Hemphill JC, Anderson C, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke 2010;41:2108–2129. Latest AHA guidelines for management of ICH patients. PubMedCrossRef
37.
Crowther M, Ageno W, Schnurr T, et al. Oral vitamin K produces a normal INR within 24 hours of its administration in most patients discontinuing warfarin. Haematologica. 2005;90:137–9.PubMed
38.
Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid Reactions to Vitamin K. Journal of Thrombosis and Thrombolysis. 2001;11:175–83.PubMedCrossRef
39.
Chong CT, Lew TW, Kuperan P, Tan JJ, Tan HL, Kwek TK. Rapid reversal of coagulopathy in warfarin-related intracranial haemorrhages with prothrombin complex concentrates. Anaesth Intensive Care. 2010;38:474–80.PubMed
40.
• Chapman SA, Irwin ED, Beal AL, Kulinski NM, Hutson KE, Thorson MA. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother 2011;45:869–875. A retrospective study of 31 patients showing more rapid reversal of the INR with addition of PCC to FFP and vitamin K. PubMedCrossRef
41.
• Robinson MT, Rabinstein AA, Meschia JF, Freeman WD. Safety of Recombinant Activated Factor VII in Patients With Warfarin-Associated Hemorrhages of the Central Nervous System. Stroke 2010;41:1459–1463. A retrospective study of 101 patients showing safety of factor rVIIa in patients with WICH. PubMedCrossRef
42.
Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4:967–70.PubMedCrossRef
43.
Taberner DA, Thomson JM, Poller L. Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. Br Med J. 1976;2:83–5.PubMedCrossRef
44.
van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res. 2006;118:313–20.PubMedCrossRef
45.
Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol. 2008;83:137–43.PubMedCrossRef
46.
• Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United kingdom. Clin Ther 2010;32:2478–2493. Study showing that PCC is more cost-effective treatment than FFP for the emergency reversal of warfarin. PubMedCrossRef
47.
Mayer SA, Brun NC, Begtrup K, et al. Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. N Engl J Med. 2008;358:2127–37.PubMedCrossRef
48.
Illanes S, Zhou W, Schwarting S, Heiland S, Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke. 2011;42:191–5.PubMedCrossRef
49.
Schlunk F, Van Cott EM, Hayakawa K, Pfeilschifter W, Lo EH, Foerch C. Recombinant Activated Coagulation Factor VII and Prothrombin Complex Concentrates Are Equally Effective in Reducing Hematoma Volume in Experimental Warfarin-Associated Intracerebral Hemorrhage. Stroke. 2012;43:246–9.PubMedCrossRef
50.
Taketomi T, Szlam F, Levy JH, Tanaka KA. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2008;19:106–8.PubMedCrossRef
51.
Diringer MN, Skolnick BE, Mayer SA, et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke. 2010;41:48–53.PubMedCrossRef
52.
Flaherty ML, Adeoye O, Sekar P, et al. The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage. Stroke. 2009;40:1738–42.PubMedCrossRef
53.
•• Steiner T, Freiberger A, Griebe M, et al. International normalised ratio normalisation in patients with coumarin-related intracranial haemorrhages—the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex—study design and protocol. International Journal of Stroke 2011;6:271–277. Ongoing randomized trial to compare safety and efficacy of FFP and PCC in WICH. PubMedCrossRef
54.
Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7:391–9.PubMedCrossRef
55.
Arima H, Wang JG, Huang Y, et al. Significance of perihematomal edema in acute intracerebral hemorrhage: the INTERACT trial. Neurology. 2009;73:1963–8.PubMedCrossRef
56.
Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387–97.PubMed
57.
•• Mendelow AD, Gregson BA, Mitchell PM, Murray GD, Rowan EN, Gholkar AR. Surgical trial in lobar intracerebral haemorrhage (STICH II) protocol. Trials 2011;12:124. The ongoing STICH II will study patients with lobar intracerebral hemorrhage and best Glasgow Coma Scale (GCS) of 5 or 6 within 48 hours of ictus to either early surgery or medical management. PubMedCrossRef
58.
Rabinstein AA, Wijdicks EFM. Determinants of Outcome in Anticoagulation-Associated Cerebral Hematoma Requiring Emergency Evacuation. Arch Neurol. 2007;64:203–6.PubMedCrossRef
59.
Chapman N, Huxley R, Anderson C, et al. Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History. Stroke. 2004;35:116–21.PubMedCrossRef
60.
•• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151. A randomized controlled trial showing that dabigatran 150 mg daily is superior to warfarin in preventing stroke or systemic embolism. PubMedCrossRef
61.
•• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–2510. A randomized, open label trial in patients with venous thromboembolism, showing that rivaroxaban’s efficacy is noninferior to enoxaparin-vitamin K antagonist. PubMedCrossRef
62.
Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost. 2011;105:535–44.PubMedCrossRef
63.
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate / Clinical Perspective. Circulation. 2011;124:1573–9.PubMedCrossRef
64.
Zhou W, Schwarting S, Illanes S, et al. Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran. Stroke. 2011;42:3594–9.PubMedCrossRef
65.
van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.PubMedCrossRef
66.
• Majeed A, Kim Y-K, Roberts RS, Holmström M, Schulman S. Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage. Stroke 2010;41:2860–2866. A retrospective study of 234 patients showing that resumption of warfarin therapy may be safe between 10 and 30 weeks after warfarin-related intracranial hemorrhage. PubMedCrossRef
67.
Maeda K, Koga M, Okada Y, et al. Nationwide survey of neuro-specialists’ opinions on anticoagulant therapy after intracerebral hemorrhage in patients with atrial fibrillation. J Neurol Sci. 2012;312:82–5.PubMedCrossRef
68.
Claassen DO, Kazemi N, Zubkov AY, Wijdicks EFM, Rabinstein AA. Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage. Arch Neurol. 2008;65:1313–8.PubMedCrossRef
69.
•• Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534–542. A multicenter, randomized non-inferiority trial compared percutaneous closure of the LAA with warfarin in patients with atrial fibrillation. PubMedCrossRef
Metadaten
Titel
Anticoagulation-Related Intracranial Hemorrhages
verfasst von
Manoj K. Mittal
Alejandro A. Rabinstein
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Atherosclerosis Reports / Ausgabe 4/2012
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0258-8

Weitere Artikel der Ausgabe 4/2012

Current Atherosclerosis Reports 4/2012 Zur Ausgabe

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Management of Ruptured Brain Arteriovenous Malformations

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

International Epidemiology of Intracerebral Hemorrhage

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Medical Versus Surgical Management of Intracerebral Hematomas

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Clinical Syndromes and Management of Intracerebral Hemorrhage

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Nonaneurysmal Subarachnoid Hemorrhage: An Update

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

The Pathophysiology and Clinical Presentation of Cerebral Amyloid Angiopathy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise